Operator
Good day, and welcome to the first-quarter 2021 Fulgent Genetics earnings call. At this time, I would like to turn the conference over to Nicole Borsje with investor relations. Please go ahead.
Nicole Borsje
Investor Relations
Great. Thanks. Good afternoon, and welcome to Fulgent Genetics first-quarter 2021 financial results conference call. On the call today are Ming Hsieh, chief executive officer; Paul Kim, chief financial officer; and Brandon Perthuis, chief commercial officer.
The company s press release discussing its financial results is available in the Investor Relations section of the company s website, fulgentgenetics.com. An audio replay of this call will be available shortly after the call concludes. Please visit the Investor Relations section of the company s website to access the audio replay. Management s prepared remarks and answers to your questions on today s call will contain forward-looking statements.
Viant Technology Inc. Announces Pricing of Upsized Initial Public Offering
February 09, 2021 19:42 ET | Source: Viant Technology Inc. Viant Technology Inc. Irvine, California, UNITED STATES
IRVINE, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) Viant Technology Inc. (NASDAQ:DSP) today announced the pricing of its upsized initial public offering of 10,000,000 shares of Class A common stock at a price to the public of $25.00 per share.
Viant Technology is offering 10,000,000 shares of Class A common stock in the offering. Existing stockholders of Viant Technology have granted the underwriters a 30-day option to purchase up to 1,500,000 shares of Class A common stock at the initial public offering price, less underwriting discounts. The Company will not receive any proceeds from the sale of the shares by the selling stockholders.
TMCnet News
Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year
[December 29, 2020]
Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year
TEMPLE CITY, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Company has extended its partnership with the New York City Department of Education (or âNYC DOEâ) and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, .
Fulgent Genetics, Inc.December 29, 2020 GMT
TEMPLE CITY, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) Fulgent Genetics (Nasdaq: FLGT), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Company has extended its partnership with the New York City Department of Education (or “NYC DOE”) and NYC Health + Hospitals for COVID-19 testing through the remainder of the 2021 school year. The contract was awarded after a competitive process where Fulgent demonstrated its COVID-19 testing capabilities, including its accurate and reliable test offerings, easy to use reporting systems and fast turnaround times.